COMMUNIQUÉS West-GlobeNewswire

Standing Ovation raises $34.2 million to scale up its breakthrough technology for producing dairy proteins through precision fermentation, offering a sovereign and sustainable response to the surge in global demand for protein
31/03/2026
PRESS RELEASE Standing Ovation raises $34.2 million to scale up its breakthrough technology for producing dairy proteins through precision fermentation, offering a sovereign and sustainable response to the surge in [...]
SAFE - Forte dynamique de développement au Venezuela
31/03/2026
Forte dynamique de développement au Venezuela Fleurieux-sur-l’Arbresle - France - le 31 mars 2026 à 8h. Après la signature d'un accord de distribution et le succès de la première chirurgie annoncés le 24 avril 2025 , [...]
Avacta announces first patient treated in Phase 1 FOCUS-01 trial of FAP-Exd (AVA6103) - a sustained-release pre|CISION® exatecan peptide drug conjugate
31/03/2026
Enrollment underway in second Avacta clinical program at first three specialist U.S. oncology centers Initial data from the trial expected later this year LONDON and PHILADELPHIA, March 31, 2026 (GLOBE NEWSWIRE) -- [...]
EURneffy 1 mg approved across the EU as the first and only needle-free adrenaline treatment for young children (≥15 kg) at risk of anaphylaxis
31/03/2026
Today, ALK announced that children aged 4 and older living with severe allergies across the EU can now access the first and only needle-free adrenaline treatment for anaphylaxis, after the European Commission (EC) [...]
CancerVax Reports Successful Initial Mouse Study with Breakthrough Results
31/03/2026
First biodistribution study of the Company’s novel targeted lipid nanoparticle achieved systemic circulation with the potential to target many types of cancer Lehi, UT, March 31, 2026 (GLOBE NEWSWIRE) -- Lehi, Utah, [...]
Communiqué de presse : Le Rezurock de Sanofi approuvé dans l’UE pour le traitement de la maladie chronique du greffon contre l’hôte
31/03/2026
Le Rezurock de Sanofi approuvé dans l’UE pour le traitement de la maladie chronique du greffon contre l’hôte Rezurock est maintenant approuvé dans l’UE pour les adultes et les enfants âgés de 12 ans et plus atteints de [...]
BioVersys Strengthens Ansamycin Platform and NTM Research Through Collaboration and License Agreement with Hackensack Meridian Health
31/03/2026
BASEL, Switzerland, March 31, 2026 (GLOBE NEWSWIRE) -- BioVersys strengthens its Ansamycin Chemistry platform and research on tackling difficult-to-treat non-tuberculous mycobacteria (NTM) diseases. BioVersys joins [...]
ONWARD Medical Reports Full Year 2025 Financial and Operating Results, Highlighting Strong US Commercial Performance and Major Pipeline Milestones
31/03/2026
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) EINDHOVEN, the Netherlands, March 31, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. ( [...]
Press Release: Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease
31/03/2026
Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease Rezurock is now approved in the EU for adults and children aged 12 years and older with chronic GVHD, providing a new medicine for patients [...]
Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases
31/03/2026
New collaboration structure achieves meaningfully improved financial terms and flexibility for Galapagos Following this transaction, the Company will continue to have a majority of its cash remaining for additional [...]
Lipella Pharmaceuticals Inc. Files Voluntary Petitions for Relief Under Chapter 11
31/03/2026
PITTSBURGH, March 30, 2026 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (“Lipella” or the “Company”), a clinical-stage biotechnology company, announced today that it filed a voluntary petition for relief under [...]
Neuro Serge Claims Evaluated: Dangers Emerge Upon Fake NeuroSerge Product Offerings Online
31/03/2026
A 2026 consumer awareness update examining NeuroSerge product name variations, unauthorized seller listings, proprietary blend transparency, ingredient research context, and what to verify before reviewing any Neuro [...]
Curanex Provides Business Update in Connection with 2025 Annual Report as Phyto-N Advances Toward Planned IND Submission
30/03/2026
Company advances manufacturing, toxicology, patent and regulatory milestones while building a broader pharmaceutical development platform Jericho, New York, March 30, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, [...]
Glucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
30/03/2026
Company prepares to file Investigational Device Exemption (IDE) for Novel CBGM Technology, targeting US Clinical Trial Launch in Second Half of 2026 US Patent and Trademark Office (USPTO) issued patents for Glucotrack’s [...]
Synergy CHC Corp. Announces Date Change of Fourth Quarter and Full Year 2025 Earnings and Conference Call
30/03/2026
WESTBROOK, Maine, March 30, 2026 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a leading consumer health and wellness company, today announced an updated date for the release of its [...]
MemoryON Claims Evaluated: Hidden Details Emerge About Memory On Brain Support Supplementation for Memory Loss
31/03/2026
A 2026 informational consumer report on MemoryON's cognitive health formula, Bacopa Monnieri and Phosphatidylserine dosage research, St. John's Wort safety considerations, nootropic ingredient analysis, pricing [...]
Alvotech files Annual Report with the SEC
31/03/2026
REYKJAVIK, ICELAND (March 30, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”) has filed its Annual Report 2025 on Form 20-F for the financial year 2025 with the U.S. Securities and Exchange Commission (SEC), [...]
Alvotech Files Annual Report with the SEC
31/03/2026
REYKJAVIK, Iceland, March 30, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) (the “Company”) has filed its Annual Report 2025 on Form 20-F for the financial year 2025 with the U.S. Securities and Exchange Commission ( [...]
Range Impact Reports Full Year 2025 Financial Results
31/03/2026
CLEVELAND, OHIO, March 30, 2026 (GLOBE NEWSWIRE) -- Range Impact, Inc. (OTC: RNGE) (“Range Impact” or the “Company”), a public company dedicated to acquiring, reclaiming and repurposing distressed coal mine properties [...]

Pages